Abigail Brooks, MA

C difficile carriers faced a higher baseline risk for hospital-onset infection compared to noncarriers, and this risk was not significantly influenced by antibiotic use.

Study reveals notable sex-based disparities in liver complication risk among adults with cirrhosis, particularly in nonviral cases.

The most successful FMT approach involved administering multiple-dose capsules or colonoscopy following an extended course of antibiotic pretreatment.

Study findings underscore the cost-effectiveness of more frequent hepatitis C testing among people who inject drugs, compared to less frequent or no testing at all.

Use of an AI-guided infection prevention bundle did not significantly reduce CDI incidence but was associated with increased antimicrobial stewardship.

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

Hydronidone demonstrated significant efficacy in liver fibrosis regression in CHB patients, meeting the primary endpoint in a phase 3 trial. The company plans to file regulatory applications in China and the US, aiming to expand the therapy's indications.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

Lower CD4+ cell counts, HCV genotype 4, and recent injection drug use were linked to unsuccessful DAA treatment in people with HCV and HIV.

Patients with autoimmune hepatitis who are deficient in vitamin D had worse outcomes than patients with normal vitamin D levels.

HCV infection was associated with elevated brachial-ankle pulse wave velocity levels in patients with ESRD receiving hemodialysis.

The Xpert HCV assay facilitates rapid HCV diagnosis in nonclinical settings, aiding high-risk populations like those under community supervision.

A new study finds that 1.4 million people aged 12-59 with current hepatitis C (HCV) infection, including over a third of them without a history of injection drug use.

A systematic review and meta-analysis finds that hepatitis B (HBV) education led by healthcare providers had the greatest impact on testing uptake.

Overall, findings demonstrated a 78% treatment success rate among patients who prematurely discontinued direct-acting antivirals (DAA), and even seeing a 93% success rate among those who discontinued after week 4.

The results indicate that paternal hepatitis B virus infection before pregnancy is linked to a 40% higher risk of congenital heart diseases in their children.

Findings affirm the safety and efficacy of using HBsAg-positive donor kidneys in HBsAg-negative recipients, with no adverse effects on posttransplant outcomes.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.

Social determinants of health may determine hepatitis C management in the outpatient setting.

HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.

Analysis reveals rising hospitalization rates among pregnant women with hepatitis C virus (HCV) and age as a critical factor influencing maternal and fetal health outcomes.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

An analysis of NHANES data looked at HCV infection and risk of prostate cancer, and found contrary evidence from previous research.

Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.

HCV seroprevalence and antigen positivity were both low, suggesting universal birth cohort screening may not be necessary or cost-effective.

Sustained virologic response (SVR) and sociodemographic factors were found to be associated with long-term improvements in health-related quality of life in patients with hepatitis C (HCV).

The XGBoost machine learning model outperformed other AI and logistic regression models for predicting DAA failure, with an AUROC of 1.000 in the training dataset and 0.803 in the validation dataset.

Patients in the integrated and standard care treatment arms reported similar SCL-10 scores indicative of psychological stress and symptom burden, both at baseline and after the completion of DAA treatment.

Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.